ORBi: Nyssen Astrid - Rapport benefice/risque des endoprotheses coronaires pharmaco-actives. 2ème partie : analyse dans la population diabétique

Reference : Rapport benefice/risque des endoprotheses coronaires pharmaco-actives. 2ème partie : ana...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Endocrinology, metabolism & nutrition Human health sciences : Cardiovascular & respiratory systems Human health sciences : Pharmacy, pharmacology & toxicology
	To cite this reference:	http://hdl.handle.net/2268/3020

Title :	Rapport benefice/risque des endoprotheses coronaires pharmaco-actives. 2ème partie : analyse dans la population diabétique
Language :	English
Alternative title :	[en] Benefit-risk ratio of coronary drug-eluting stents : 2nd part : evaluation in the diabetic population
Author, co-author :	Nyssen, Astrid [Université de Liège - ULg > > > 3 doc médecine >]
	Legrand, Victor [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
	Scheen, André [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Publication date :	Nov-2008
Journal title :	Revue Médicale de Liège
Publisher :	Hopital de Baviere
Volume :	63
Issue/season :	11
Pages :	654-661
ISSN :	0370-629X
City :	Liège
Country :	Belgique
Keywords :	[en] Coronary Artery Disease ; Angioplasty ; Drug-eluting stent ; Restenosis ; Thrombosis ; Paclitaxel ; Sirolimus
Abstract :	[en] The diabetic patient is at high risk of coronary heart disease. He/she can benefit of revascularisation procedures, even if he/she is exposed to a higher incidence of complications after a coronary artery bypass graft or a percutaneous transluminal coronary angioplasty. The use of drug-eluting stents — paclitaxel (PES) or sirolimus (SES) — dramatically reduces the risk of restenosis as compared to bare-metal stents; nevertheless, the rate of restenosis remains almost double in diabetic patients compared to that observed in non-diabetic subjects. However, the risk of (very) late thrombosis is higher with drug-eluting stents than with bare-metal stents, in the diabetic population as in the non-diabetic population. Altogether, among diabetic patients, the incidence of major cardiovascular events is significantly reduced with drug-eluting stents. This global clinical benefit essentially results from a diminution of revascularisation procedures rather than from a reduction of myocardial infarcts or cardiovascular deaths. Comparison between SES and PES gives discordant results. Indeed, while the loss of intra-stent lumen is more important with PES than with SES, PES are associated with a lower rate of major cardiovascular events than SES. Efficacious antiplatelet therapy in the long run is mandatory in all diabetic patients treated with drug-eluting stents
Target :	Researchers ; Professionals ; Students
Permalink :	http://hdl.handle.net/2268/3020
Other URL :	http://www.rmlg.ulg.ac.be/index.php?page=resume?num_id=1816

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	200811_05.pdf	No commentary	Publisher postprint	385.2 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5